Melinta Therapeutics
Company
Melinta Therapeutics develops one asset, approved (Minocin). Mostly small molecule.
- 1
- Asset
- Furthest stage
- Approved
- 9
- Trials
- 0
- Signals
Pipeline
1Tetracycline-class broad-spectrum antibiotic that inhibits bacterial protein synthesis.
Approved, Small molecule, acute renal insufficiency (Phase 1), chronic renal insufficiency (Phase 1)
Full company profiles: pipeline, trials, funding and people.
Subsidiaries
11 asset, 5 trials
In the full profile
- Evidence behind the mechanisms1
- Trials9
- Similar companies6